- Curative Biotechnology ( OTCPK:CUBT ) intends to offer shares of its common stock for sale in an underwritten public offering, after giving effect to the company’s proposed 1-for-400 reverse stock split.
- The company expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
- The company intends to use the net proceeds from this offering for working capital and general corporate purposes.
- The company has applied to list its common stock on the NYSE American under the symbol “CUBT”.
For further details see:
Curative Biotechnology intends to offer an underwritten public offering; to uplist to NYSE